UNIVEST FINANCIAL Corp Decreases Holdings in Stryker Co. (NYSE:SYK)

UNIVEST FINANCIAL Corp reduced its stake in Stryker Co. (NYSE:SYK) by 8.0% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 2,123 shares of the medical technology company’s stock after selling 185 shares during the quarter. UNIVEST FINANCIAL Corp’s holdings in Stryker were worth $764,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the stock. Kohmann Bosshard Financial Services LLC purchased a new stake in Stryker in the fourth quarter worth $25,000. Dunhill Financial LLC grew its stake in shares of Stryker by 94.9% during the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 37 shares during the period. Rakuten Securities Inc. increased its holdings in Stryker by 618.2% in the 4th quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company’s stock worth $28,000 after acquiring an additional 68 shares during the last quarter. Centricity Wealth Management LLC bought a new stake in Stryker in the 4th quarter valued at about $30,000. Finally, BankPlus Trust Department purchased a new stake in Stryker during the fourth quarter valued at about $33,000. Institutional investors own 77.09% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on SYK shares. Morgan Stanley upgraded shares of Stryker from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $370.00 to $445.00 in a research note on Monday, December 2nd. StockNews.com lowered shares of Stryker from a “buy” rating to a “hold” rating in a research note on Thursday, March 6th. Truist Financial increased their target price on Stryker from $409.00 to $413.00 and gave the stock a “hold” rating in a research report on Thursday, January 30th. Canaccord Genuity Group lifted their price target on Stryker from $420.00 to $435.00 and gave the company a “buy” rating in a research report on Wednesday, January 29th. Finally, Needham & Company LLC reissued a “buy” rating and set a $442.00 price objective on shares of Stryker in a report on Friday, March 21st. Five research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to MarketBeat, Stryker has a consensus rating of “Moderate Buy” and an average target price of $421.90.

Insider Activity

In other news, Director Ronda E. Stryker sold 201,392 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $392.24, for a total value of $78,993,998.08. Following the transaction, the director now owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. This represents a 5.24 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Allan C. Golston sold 2,458 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the sale, the director now directly owns 14,895 shares of the company’s stock, valued at $5,705,827.65. This trade represents a 14.16 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 5.90% of the company’s stock.

Stryker Trading Down 1.5 %

NYSE:SYK opened at $367.34 on Thursday. Stryker Co. has a 12 month low of $314.93 and a 12 month high of $406.19. The company has a current ratio of 1.95, a quick ratio of 1.32 and a debt-to-equity ratio of 0.59. The company has a 50-day moving average price of $384.74 and a 200-day moving average price of $374.29. The stock has a market cap of $140.17 billion, a price-to-earnings ratio of 47.34, a P/E/G ratio of 2.93 and a beta of 0.95.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter last year, the company earned $3.46 EPS. Equities analysts predict that Stryker Co. will post 13.47 EPS for the current year.

Stryker Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be paid a $0.84 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.91%. Stryker’s dividend payout ratio is currently 43.30%.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.